Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating oral doses of BI 113823 in patients with knee osteoarthr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• BI 113823

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Osteoarthritis | Phase 1 | Status: TERMINATED